Примери за използване на Package leaflets на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The package leaflets should be updated accordingly.
You should also read the package leaflets for these medicines.
The package leaflets should be updated accordingly.
About these medicines is described in separate package leaflets.
See also the package leaflets for peginterferon alfa and ribavirin.
Хората също превеждат
Annex III Amendments to the summaries of product characteristics and package leaflets.
Refer to the Package Leaflets of these other medicines for guidance on how to take them.
Amendments in the relevant sections of the Summaries of Product Characteristics and package leaflets.
For further information, see the package leaflets for Kisplyx and the medicine containing everolimus.
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets.
See the package leaflets for these medicines for additional information on their use and effects.
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets.
Please refer to the Package Leaflets of these other medicines for guidance on how to take them.
Grounds for amendment of the summaries of product characteristics,labelling and package leaflets.
You must read the package leaflets for peginterferon alfa and ribavirin for additional information.
Amendments in the relevant sections of the summary of product characteristics,labelling and package leaflets.
See also the package leaflets for peginterferon alfa and ribavirin for side effects reported for these.
Annex III Amendments to relevant sections of the summaries of product characteristics and package leaflets.
Read the package leaflets for these medicines for their dosage and directions on‘how to take' them.
Amendments to relevant sections of the summary of product characteristics and the package leaflets.
You should therefore carefully read the Package Leaflets of ritonavir and your other antiretroviral medicines.
Amendments to the relevant sections of the summaries of product characteristics and package leaflets.
Please read the package leaflets for the individual medicines you are given for further information on these medicines.
Amendments in the relevant sections of the summaries of product characteristics,labelling and package leaflets.
You should therefore carefully read the Package Leaflets of ritonavir and your child's other antiretroviral medicines.
Annex III Amendments to relevant sections of the summary of product characteristics and package leaflets.
Please read the package leaflets for the other medicines that are part of your treatment, to see if they are suitable for you.
Grounds for amendment of the summaries of product characteristics,labelling and package leaflets.
The amended Summaries of Product Characteristics and package leaflets of the reference Member State are set out in Annex III.
More information on the restrictions on the use of medicines radiolabelled with Cuprymina will be found in their package leaflets.